The Company advises the Staff that on May 19, 2021, representatives of Goldman Sachs, the lead underwriters (the
“Lead Underwriters”) for the IPO, on behalf of the underwriters, advised the Company that, based on then-current market conditions, they anticipated that the underwriters would recommend to the Company a preliminary price range of
$[****]1 to $[****]2 per share (the “Preliminary Price Range”), resulting in a midpoint of the Preliminary Price
Range of $[****]3 per share (the “Midpoint Price”).
The Company further advises the Staff that the Preliminary Price Range represents the
Rest of the answer
Company’s belief of what the indicative price range to be disclosed in the preliminary prospectus may be, but that the actual indicative price range to be included in the preliminary prospectus will not be determined until the Company completes a valuation process with the underwriters and will be narrower than the Preliminary Price Range. This valuation process is expected to occur shortly before the printing and filing of the preliminary prospectus for the commencement of the roadshow for the IPO. Therefore, the Preliminary Price Range is subject to further change, which may result from various factors, including then-current market conditions and subsequent business, market, and other developments affecting the Company. The indicative price range to be included in the preliminary prospectus, when determined, will be included in an amendment to the Registration Statement prior to the distribution of any preliminary prospectuses to potential investors.
The Company previously responded to comment #26 in the SEC comment letter dated March 15, 2021 regarding the fair value assumptions used to determine share-based compensation expense in accordance with ASC 718, for equity grants in the year ended December 31, 2020 through February 11, 2021. In this response, the Company has updated the table that includes the details and fair value assumptions for grants after February 11, 2021 through the date of this letter and has provided general commentary on the fluctuations in the estimated fair value of its common stock. For grants between March 6, 2021 through the date of this letter, the Company’s estimated fair value used to measure share-based compensation ranged from $22.34 to $24.21 as shown in the table below.
[****]–Confidential Treatment Requested by Marqeta, Inc.
Equity Award Issuances by the Company after February 11, 2021
Grant Date
Estimated Fair Value of
Common Stock Used in the Determination of
Fair Value of the
Equity Award (a)
Number of
RSU’s Granted
Aggregate Grant
Date Fair Value of RSUs (b)
Options
Granted
Grant Date Fair
Value of Options
(c)
Date Fair Value of
3/6/2021
$
22.34
19,663
439,271 n/a
3/30/2021
23.64
333,476
7,883,373
4/7/2021
23.93
1,000,000
12.33
12,330,000
4/12/2021
24.10
198,163
4,775,728
20,460,923
12.46
216,821,200
5/5/21 (d)
24.21
2,972,750
71,970,278
722,267
11.96
8,611,040
5/12/21 (d)
20,000
484,200
250,000
2,990,000
(a):
The fair value of the underlying shares of common stock on each respective date represents the valuation on the respective date, which is a linear interpolation between the Company’s valuation dates.
(b):
Aggregate grant date fair value of RSUs is equal to the number of RSUs multiplied by the fair value of the common stock on the grant date.
(c):
Grant date fair value of options was determined using a Black-Scholes option pricing model, with the exception of the CEO grant issued on April 12, 2021 for 19,740,923 and on May 5, 2021 for 47,267 shares, which were valued using a Monte Carlo Simulation Model.
(d):
The fair value of the underlying shares of common stock on May 5, 2021 and May 12, 2021 equals the estimated fair value determined as of the most recent valuation date of April 15, 2021. Consistent with the Company’s past practice, the Company will evaluate the need to perform a linear interpolation between the April 15, 2021 estimated fair value and the ultimate IPO price.
General Commentary on Changes in the Estimated Fair Value of Common Stock
The increase in the estimated per share fair value of the Company’s common stock from February 2021 to May 2021 is attributable to additional weighting to the IPO scenario due to continued progression towards the IPO, stronger than expected results in the first quarter of 2021, and an increase in the weighted-average secondary sale prices observed.
•
IPO Scenario – The Company increased the weighting on the IPO scenario in the PWERM in February to 70%, compared to 65% in the prior Valuation Report, and then again to 75% in the April Valuation Report. The Company continued to take significant steps in the IPO process, including submission of the first registration statement draft on
February 16, 2021, responding to the Staff’s comments to the draft registration statement, submission of the second and third registration statement drafts on April 2, 2021 and April 30, 2021, respectively, and a public filing of the Registration Statement on May 14, 2021.
The results of the first quarter ended March 31, 2021 exceeded the Company’s plan. Actual net revenue for the first quarter of 2021 exceeded the Company’s original plan by 15%.
Secondary Sale Prices – in 2021, the Company observed an increase in the transaction prices of secondary sales of common stock to new and existing stockholders of the Company. The weighted-average price of the secondary sales used in the estimation of the fair value of the Company’s common stock for the February 16, 2021, March 15, 2021 and April 15, 2021 valuation dates were $28.52, $31.92, and $32.66, respectively.
Analysis of Differences Between
Share-Based Compensation Expense for 2021 Grants and Midpoint Price
As noted above, the Preliminary Price Range is between $[****]4 to $[****]5 per share of common stock. The Preliminary Price Range was determined based, in part, on discussions among the management of the
Company, the Company’s Board of Directors, and the Lead Underwriters.
The Company observes that for all grants after
February 11, 2021 through the date of this letter, the Company used an estimated fair value of the Company’s common stock that is [****]6 the Preliminary Price Range. Further, the overwhelming majority of the grants after February 11, 2021 to the date of this letter, were valued using an estimated common share value that [****]7 the midpoint price.
Based on the above analysis, the Company respectfully submits to the Staff that the determination of the fair value of its common stock described above was in accordance with ASC Topic 718 and consistent with the AICPA Practice Guide.
*****
If you require any additional information on the matters contained in this letter, or if we can provide you with any other information that will facilitate your review, please advise us at your earliest convenience. You may reach me at (415) 733-6017 or [email protected].